Abliva
0,245 SEK -5,96%Vær den første som følger denne virksomhed
Abliva is a pharmaceutical company. The company develops drugs for the treatment of primary mitochondrial diseases. These congenital, rare and often very serious diseases occur when the cell's energy supply, the mitochondria, does not function properly. The portfolio includes projects in various stages and ranges from the early detection phase to the clinical phase. The company was previously known as NeuroVive Pharmaceutical.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ABLI
Daglig lav / høj pris
0,242 / 0,26
SEK
Markedsværdi
394,11 mio. SEK
Aktieomsætning
1,32 mio. SEK
Volumen
5,3 mio.
Seneste videoer
Finanskalender
Delårsrapport
22.08.2024
Delårsrapport
21.11.2024
Årsrapport
21.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Hadean Capital I AS | 22,4 % | 22,4 % |
Oslo Pensjonsforsikring AS | 14,9 % | 14,9 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion
Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools